Fotagliptin

A pharmaceutical drug used in the treatment of type 2 diabetes

File:Fotagliptin.svg

Chemical structure of Fotagliptin

Fotagliptin is a pharmaceutical drug that belongs to the class of medications known as DPP-4 inhibitors. It is primarily used in the management of type 2 diabetes mellitus, a chronic condition characterized by high blood sugar levels due to insulin resistance and relative insulin deficiency.

Mechanism of Action

Fotagliptin works by inhibiting the enzyme DPP-4, which is responsible for the degradation of incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These hormones play a crucial role in the regulation of glucose metabolism by enhancing insulin secretion from the pancreas in a glucose-dependent manner and suppressing glucagon release. By inhibiting DPP-4, fotagliptin increases the levels of active incretin hormones, thereby improving glycemic control in patients with type 2 diabetes.

Pharmacokinetics

Fotagliptin is administered orally and is absorbed into the bloodstream, where it exerts its effects on the DPP-4 enzyme. The pharmacokinetic profile of fotagliptin includes its absorption, distribution, metabolism, and excretion. It is metabolized primarily in the liver and excreted through the kidneys. The half-life of fotagliptin allows for once-daily dosing, which can improve patient adherence to the treatment regimen.

Clinical Use

Fotagliptin is indicated for the treatment of type 2 diabetes in adults. It can be used as monotherapy or in combination with other antidiabetic agents such as metformin, sulfonylureas, or insulin. The choice of combination therapy depends on the individual patient's needs, glycemic targets, and the presence of any contraindications or comorbidities.

Side Effects

Common side effects of fotagliptin include nasopharyngitis, headache, and upper respiratory tract infection. As with other DPP-4 inhibitors, there is a potential risk of pancreatitis, although this is rare. Patients should be monitored for signs and symptoms of pancreatitis, and the medication should be discontinued if pancreatitis is suspected.

Contraindications

Fotagliptin is contraindicated in patients with a known hypersensitivity to the drug or any of its components. It should be used with caution in patients with severe renal impairment or end-stage renal disease, as dose adjustments may be necessary.

Related pages

• Type 2 diabetes mellitus
• Dipeptidyl peptidase-4 inhibitors
• Glucagon-like peptide-1
• Metformin